Mycobacterium Avium-Intracellulare Infection Clinical Trial
Official title:
A Randomized, Double-Blinded, Placebo-Controlled, Phase II Study of the Safety and Efficacy of Inhaled Interferon Gamma-1b With Antimycobacterial in Previously Treated or Moderate to Severe Pulmonary Mycobacterium Avium Complex (MAC) Infection
This study will test the safety and effectiveness of inhaled interferon gamma-1b and oral
antibiotics for treating mycobacterium avium complex (MAC) infection of the lungs.
Patients 18 years of age or older with MAC infection of the lungs who 1) have been
previously treated for MAC, or 2) have moderate or severe lung disease due to MAC that has
not been previously treated may be eligible for this study.
Participants will be randomly assigned to one of two treatment groups. Group 1 will receive
500 micrograms of interferon gamma-1b 3 times a week for 48 weeks by inhalation. Group 2
will inhale a placebo (inactive substance) according to the same regimen. In addition, all
patients will receive standard MAC treatment with three antibiotics-clarithromycin or
azithromycin, ethambutol and rifampin or rifabutin-taken by mouth times a week.
Patients will come to the clinic for a screening visit, baseline visit, 1 month after
beginning treatment, and at 3-month intervals thereafter until the end of the study. During
these various visits, they will undergo the following tests and procedures:
- Medical history and physical examination, including height and weight measurements,
heart rate, breathing rate, blood pressure and temperature
- Possibly computed tomography (CT) and X-ray of the lungs
- Sputum sample
- Pulmonary function studies
- Blood and urine tests
Patients' eyes will be examined monthly to check for side effects of ethambutol, and hearing
and balance will be tested to check for side effects of clarithromycin or azithromycin.
At the baseline visit, the patient or caretaker will be trained to use a nebulizer (a
special breathing device) to take the study medication.
Nontuberculous mycobacterial infections due to Mycobacterium avium complex (MAC) are a growing problem among older Americans, especially women. These organisms are relatively resistant to antituberculous medications and frequently persist or recur. In patients with disseminated infections, interferon gamma has been shown to be a critical cytokine in the resistance to and therapy of these infections. Previous experience with injected interferon gamma has been relatively disappointing, with clinical response rates in conventional therapy-refractory patients of about 20%. Aerosol administration of interferon gamma has been shown to rapidly convert sputum smears to negative in multidrug resistant tuberculosis and in one case of MAC infection. However, in these short-term experiments, cultures have remained positive and patients have had clinical relapse. In addition, aerosol administration of interferon gamma has significantly less systemic activation and side effects than does systemic administration. Therefore, we propose to administer interferon gamma by aerosol into the lungs of patients with MAC infection that has persisted despite adequate conventional therapy. This aerosol will be delivered 3 times weekly by the patient. This trial is randomized and double blinded. The period of therapy is 48 weeks and the follow up is another 48 weeks. All patients must be on conventional therapy at the same time and have organisms that are macrolide sensitive. Screening and treatment will be conducted at the NIH Clinical Center as well as multiple collaborative sites. This study should clarify the therapeutic role for aerosolized interferon gamma in the treatment of nontuberculous mycobacterial infections. ;
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00000883 -
Long-Term Assessment for Metabolic, Cardiovascular and Neurologic Problems in HIV-Infected Patients With Increased CD4 Cells Counts Following Anti-HIV Therapy
|
N/A | |
Completed |
NCT00111397 -
Adjuvant Cytokine Therapy to Treat Pulmonary Mycobacterium Avium Complex Infection
|
Phase 1 | |
Completed |
NCT00004689 -
Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease
|
Phase 2 | |
Completed |
NCT00001763 -
Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex Infection
|
Phase 1 | |
Recruiting |
NCT05824988 -
Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease
|
||
Completed |
NCT00001030 -
The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients
|
Phase 3 | |
Completed |
NCT00002032 -
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial
|
N/A | |
Completed |
NCT00002122 -
A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients
|
Phase 3 | |
Completed |
NCT00002058 -
A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease
|
N/A | |
Completed |
NCT00002089 -
An Open-Label Study of the Use of Azithromycin in Patients With Symptomatic Disseminated Mycobacterium Avium-Intracellulare Complex (MAC) Infection Failing Current Therapy
|
N/A | |
Completed |
NCT00002309 -
A Study of Azithromycin in the Prevention of Mycobacterium Avium Complex Disease (MAC) in HIV-Infected Patients
|
N/A | |
Completed |
NCT00000641 -
A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.
|
Phase 2 | |
Completed |
NCT00002192 -
Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.
|
Phase 2 | |
Completed |
NCT00000895 -
A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection
|
N/A | |
Completed |
NCT00002140 -
A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients
|
Phase 3 | |
Completed |
NCT00001023 -
The Safety and Effectiveness of Rifabutin, Combined With Clarithromycin or Azithromycin, in HIV-Infected Patients
|
N/A | |
Completed |
NCT00001995 -
A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Complex (MAC) Bacteremia in Patients With AIDS
|
N/A | |
Completed |
NCT00000971 -
The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children With AIDS
|
Phase 1 | |
Completed |
NCT00002101 -
A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo
|
Phase 3 | |
Completed |
NCT00000644 -
A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. Avium Complex (MAC) Infections in Patients With AIDS
|
Phase 2 |